GPR37L1 Antibody

What is GPR37L1 and why is it significant in neuroscience research?

GPR37L1 (G protein-coupled receptor 37-like 1) is a 481 amino acid orphan 7-transmembrane receptor with a calculated molecular weight of approximately 53 kDa that shares structural homology with the endothelin receptor family of GPCRs . The receptor is particularly significant in neuroscience research because it is expressed predominantly in glial cells within the central nervous system, including cerebellar Bergmann glia, cerebral cortex, and internal capsule fibers . Recent studies have revealed its neuroprotective functions during ischemia, likely through modulation of extracellular glutamate concentration and NMDAR activation, making it an important target for understanding glial-neuronal interactions and neuroprotective mechanisms .

What alternative names for GPR37L1 should researchers be aware of when searching literature?

When conducting literature searches or ordering antibodies, researchers should be aware that GPR37L1 may be listed under several alternative designations, including ET(B)R-LP-2, ETBR-LP-2, ETBRLP2, endothelin B receptor-like protein 2, and endothelin type B receptor-like protein 2 . This nomenclature diversity reflects the receptor's initial identification through homology with endothelin receptors, although functional studies have since demonstrated that GPR37L1 does not bind known endothelin B family members .

What types of GPR37L1 antibodies are available and how should researchers select the most appropriate one for their experiments?

Researchers have access to various GPR37L1 antibodies that differ in host species, clonality, and target epitopes. Monoclonal antibodies like MAB4449 offer consistency between batches and high specificity for human GPR37L1 , while polyclonal antibodies may provide stronger signals through recognition of multiple epitopes. For studying the receptor's extracellular domain, antibodies targeting the N-terminus, such as those recognizing amino acid residues 66-80 of rat GPR37L1, are available . Selection criteria should include: (1) the species being studied, with consideration for cross-reactivity (human and rodent extracellular portions share 85% amino acid identity); (2) the intended application (Western blot, immunohistochemistry, flow cytometry); (3) whether native protein conformation needs to be preserved; and (4) whether the experiment requires detection of specific domains of the receptor .

What methodologies are recommended for validating GPR37L1 antibody specificity?

Proper validation of GPR37L1 antibodies should include multiple complementary approaches. Western blot analysis comparing wild-type tissue with negative controls is fundamental, as demonstrated with mouse and rat brain membranes . Preincubation of the antibody with its corresponding blocking peptide should eliminate specific signals . For immunohistochemistry applications, validation should include testing on GPR37L1 knockout tissue or comparing with in situ hybridization patterns. Flow cytometry validation can be performed using cells known to express GPR37L1, such as the A172 human glioblastoma cell line, comparing with appropriate isotype controls . For more rigorous validation, researchers should consider heterologous expression systems where GPR37L1 is overexpressed or knocked down, followed by antibody testing to confirm signal correlation with expression levels .

How can researchers troubleshoot non-specific binding when using GPR37L1 antibodies?

Non-specific binding is a common challenge with GPR37L1 antibodies given the receptor's structural similarity to other proteins. To minimize this issue: (1) Optimize antibody concentration through titration experiments, generally starting at the manufacturer's recommended dilution (often 1:200 for Western blot applications) and adjusting as needed . (2) Increase blocking stringency using 5% BSA or milk in TBS-T, considering the addition of 0.1% Triton X-100 for membrane proteins. (3) Include appropriate controls including pre-absorption with blocking peptides specific to the antibody epitope, which should eliminate specific signals while leaving non-specific binding intact . (4) Consider cross-adsorption against related proteins, particularly GPR37, to improve specificity. (5) For immunohistochemistry, use antigen retrieval methods appropriate for membrane proteins and extend washing steps to reduce background .

What are the optimal tissue preparation methods for GPR37L1 immunohistochemistry in brain sections?

Successful immunohistochemical detection of GPR37L1 in brain tissue requires careful consideration of fixation and preparation techniques to preserve epitope accessibility while maintaining tissue morphology. For optimal results with perfusion-fixed frozen rat brain sections, a protocol employing 4% paraformaldehyde perfusion followed by cryoprotection and sectioning at 20-30μm thickness has proven effective . When using GPR37L1 antibodies targeting extracellular epitopes (such as the N-terminal region), mild antigen retrieval methods are preferable to avoid disrupting membrane protein conformation. For visualization, secondary antibody systems such as goat anti-rabbit-AlexaFluor-488 have successfully demonstrated GPR37L1 immunoreactivity around Purkinje cell soma and in the molecular layer of cerebellum . Including DAPI counterstain helps identify cellular relationships, particularly important given GPR37L1's predominant expression in glial cells adjacent to neurons.

How can flow cytometry be effectively used to detect GPR37L1 expression in different cell populations?

Flow cytometry offers a powerful approach for quantifying GPR37L1 expression across cell populations and under different experimental conditions. For intracellular detection in cell lines such as A172 human glioblastoma, cells should be fixed with paraformaldehyde and permeabilized with saponin before antibody staining . For cell surface detection in live intact cells (e.g., BV-2 microglia), direct antibody application without fixation is appropriate, typically using approximately 2.5μg of primary antibody followed by fluorophore-conjugated secondary antibodies . Critical controls include isotype-matched control antibodies (such as MAB003 when using mouse monoclonal anti-GPR37L1) and secondary-only controls to establish gating parameters . When comparing GPR37L1 expression between conditions or treatments, mean fluorescence intensity should be normalized to account for batch-to-batch variations, and multicolor staining with cell-type specific markers can help identify GPR37L1-expressing subpopulations in heterogeneous samples.

What considerations are important when designing Western blot experiments to detect GPR37L1?

Western blot detection of GPR37L1 requires special attention to sample preparation and experimental conditions due to its nature as a transmembrane protein. For optimal results: (1) Prepare membrane-enriched fractions from tissues or cells, as demonstrated with mouse and rat brain membrane preparations . (2) Include appropriate reducing agents and denature samples at moderate temperatures (70°C rather than boiling) to prevent aggregation of membrane proteins. (3) Use gradient gels (4-12%) for better resolution of the approximately 53 kDa protein. (4) For transfer, consider semi-dry transfer methods with low SDS concentration buffers. (5) Block with 5% BSA rather than milk for phospho-specific detection. (6) Primary antibody dilutions typically range from 1:200 to 1:1000 depending on the specific antibody . (7) Include positive controls such as brain tissue lysates and negative controls including antibody preincubated with blocking peptide . The anticipated molecular weight may vary from the calculated 53 kDa due to post-translational modifications, particularly glycosylation of the extracellular domain.

How can GPR37L1 antibodies be utilized to investigate the receptor's role in neuroprotection during ischemia?

GPR37L1 antibodies provide valuable tools for investigating the receptor's upregulation and neuroprotective function during ischemic conditions. For in vivo studies, researchers can employ GPR37L1 antibodies in immunohistochemical analyses of brain sections from ischemic models (such as MCAO) to quantify expression changes in relation to the lesion core and penumbra . Double-labeling with astrocyte markers (GFAP) and neuronal markers (NeuN) can help establish the cellular context of GPR37L1 upregulation. For ex vivo applications, organotypic brain slice cultures subjected to oxygen-glucose deprivation provide a controlled system for manipulating GPR37L1 signaling while monitoring neuronal viability . Researchers can test the effects of prosaptide (a GPR37L1 ligand) treatment while using the antibodies to confirm receptor expression and localization. Additionally, co-immunoprecipitation experiments using GPR37L1 antibodies can help identify binding partners that mediate its interaction with glutamate transporters, providing mechanistic insights into how GPR37L1 modulates extracellular glutamate concentration and NMDAR activation during ischemic events .

What methodological approaches can be used to study the interaction between GPR37L1 and its ligand prosaposin/prosaptide?

Investigating the interaction between GPR37L1 and its ligand prosaposin/prosaptide requires multiple complementary techniques. Co-immunoprecipitation experiments using anti-GPR37L1 antibodies can confirm the physical interaction in native tissues or transfected cell systems, with Western blot analysis for prosaposin in the precipitated complexes . For spatial analysis, proximity ligation assays using GPR37L1 antibodies combined with prosaposin antibodies can visualize interactions at the subcellular level. Functional studies should incorporate electrophysiological recordings in systems where GPR37L1 signaling affects glutamate transporters and NMDAR activity . Researchers can apply prosaptide while monitoring glutamate transporter currents in astrocytes and then confirm GPR37L1 involvement using genetic approaches (siRNA knockdown or knockout models). Binding assays using purified proteins or membrane preparations can determine affinity constants, while mutation studies targeting the extracellular domain recognized by available antibodies can identify critical residues for ligand binding. Importantly, parallel experiments should be conducted in systems expressing the related receptor GPR37 to establish binding specificity .

How can GPR37L1 antibodies be employed in studies investigating differential expression patterns in pathological brain states?

GPR37L1 antibodies provide powerful tools for mapping expression changes across various neurological conditions. For comparative studies of GPR37L1 expression in healthy versus pathological tissue, researchers should employ quantitative immunohistochemistry with standardized protocols across samples . This approach allows for both qualitative assessment of anatomical distribution shifts and quantitative measurement of expression levels. In animal models of neurological disorders, time-course studies using GPR37L1 antibodies can reveal dynamic expression changes during disease progression. For human tissue analysis, immunohistochemistry on post-mortem samples from patients with conditions such as ischemic stroke, Parkinson's disease, or glioblastoma can identify disease-specific alterations . Flow cytometry with GPR37L1 antibodies can quantify expression changes in isolated glial populations from animal models, allowing correlation with functional readouts . Western blot analysis provides complementary quantitative data on protein levels, while co-labeling with cell-type-specific markers helps identify whether expression changes reflect altered cellular composition or regulation within specific cell types . Given GPR37L1's relationship to neuroprotection, these expression studies may identify conditions where targeting the receptor could have therapeutic potential.

What strategies can resolve inconsistent GPR37L1 antibody staining patterns between experiments?

Inconsistent staining patterns with GPR37L1 antibodies may result from several factors that can be systematically addressed. First, standardize fixation protocols—particularly critical for membrane proteins—by controlling fixative concentration, duration, and temperature . For frozen tissues, minimize freeze-thaw cycles and maintain consistent sectioning thickness (20-30μm recommended). When working with multiple antibody lots, perform side-by-side validation using known positive controls (cerebellar tissue shows reliable GPR37L1 expression patterns) . For antigen retrieval, mild methods such as sodium citrate buffer (pH 6.0) at lower temperatures may preserve membrane protein epitopes better than harsh conditions. If signals vary between samples, consider tissue-specific autofluorescence (especially in aged brain tissue) and implement appropriate quenching methods or spectral unmixing. Finally, automated immunostaining platforms can reduce operator variability, while quantitative image analysis using consistent acquisition parameters and thresholding criteria will provide more objective comparisons between experimental conditions .

How should researchers interpret and troubleshoot multiple bands in Western blots using GPR37L1 antibodies?

Multiple bands in GPR37L1 Western blots require careful interpretation, as they may represent biologically relevant forms or technical artifacts. GPR37L1 can exist in different post-translationally modified states, particularly varying glycosylation patterns that affect apparent molecular weight . The predicted core protein weight is approximately 53 kDa, but bands may appear at higher molecular weights due to glycosylation or lower weights from proteolytic processing . To distinguish between specific and non-specific bands: (1) Compare band patterns with those shown in validated publications and manufacturer data . (2) Use peptide competition assays—specific bands should disappear when the antibody is pre-incubated with its immunizing peptide . (3) Test samples from GPR37L1 knockout tissues as negative controls . (4) For suspected glycosylation variants, treat samples with glycosidases (PNGase F) before Western blotting to collapse multiple bands to the core protein size. (5) If proteolytic fragments are suspected, include protease inhibitors during sample preparation and consider mild extraction conditions to preserve protein integrity .

What approaches can address challenges in detecting low levels of GPR37L1 expression in certain cell types?

Detecting low-abundance GPR37L1 in certain cell populations requires enhancing sensitivity while maintaining specificity. For immunohistochemistry, signal amplification systems such as tyramide signal amplification (TSA) can significantly boost detection sensitivity for low-expression samples . When using confocal microscopy, optimize acquisition parameters (increasing PMT gain, extending pixel dwell time) while controlling for background. For Western blot detection of low-abundance samples, concentrate protein through immunoprecipitation with GPR37L1 antibodies before analysis . Enhanced chemiluminescence (ECL) substrates with extended exposure times can improve detection, though care must be taken to avoid overexposure of stronger signals. For flow cytometry, indirect staining with bright fluorophores (PE or APC) provides better sensitivity than direct conjugates, and signal-to-noise ratio can be improved by careful titration of primary and secondary antibodies . Parallel quantitative PCR analysis of GPR37L1 mRNA can complement protein detection methods by confirming transcript presence in samples with potentially sub-detection threshold protein levels . Finally, enrichment of specific cell populations through techniques such as fluorescence-activated cell sorting or magnetic separation prior to analysis can concentrate target cells and improve detection probability.

How might GPR37L1 antibodies be utilized in studying the receptor's potential role in neurodegenerative diseases beyond ischemia?

GPR37L1 antibodies provide essential tools for investigating this receptor's involvement in various neurodegenerative contexts beyond ischemia. In Alzheimer's disease models, researchers could use GPR37L1 antibodies to examine expression patterns in relation to amyloid plaques and neurofibrillary tangles, potentially revealing correlations with disease progression . Co-localization studies with markers of reactive astrogliosis could determine whether GPR37L1 expression changes are part of the astrocytic response to pathology. In Parkinson's disease investigation, the relationship between GPR37L1 and its homolog GPR37 (which accumulates in juvenile Parkinson's disease neurons) warrants exploration through differential antibody staining . For multiple sclerosis and demyelinating disorder research, GPR37L1 antibodies could help characterize expression in oligodendrocyte precursors during remyelination attempts . Additionally, therapeutic antibody approaches might be developed to modulate GPR37L1 signaling, potentially enhancing its neuroprotective functions in degenerative conditions. Such interventions would require careful epitope selection to trigger or inhibit specific signaling pathways downstream of the receptor.

What methodological advancements might improve in vivo imaging of GPR37L1 expression and function?

Future advancements in GPR37L1 visualization may overcome current limitations in studying its dynamic expression and function in vivo. Development of fluorescently-tagged monoclonal antibody fragments (Fabs) that can cross the blood-brain barrier would allow non-invasive imaging of GPR37L1 expression changes during disease progression or after therapeutic interventions . For animal studies, GPR37L1 reporter mouse lines using Cre-lox technology could enable cell-specific visualization of receptor expression patterns throughout development and in disease models . Advanced tissue clearing techniques combined with GPR37L1 antibody labeling may provide unprecedented three-dimensional maps of receptor distribution across entire brain regions. For functional studies, development of conformation-specific antibodies that distinguish between active and inactive receptor states could reveal spatial patterns of GPR37L1 activation in response to stimuli or during pathological processes . Finally, engineering bispecific antibodies that simultaneously target GPR37L1 and its binding partners could provide insights into the dynamic protein complexes formed during signaling events, potentially visualized through advanced microscopy techniques such as FRET or FLIM.

How can GPR37L1 antibodies contribute to developing therapeutic strategies targeting glial-neuronal interactions?

GPR37L1 antibodies will be instrumental in developing targeted therapies that modulate glial-neuronal interactions through this receptor. For therapeutic development, antibodies can help screen and validate small molecule modulators by confirming their binding specificity and effects on receptor expression or localization . In preclinical efficacy studies of GPR37L1-targeting compounds, antibodies provide critical tools for confirming target engagement in vivo. The neuroprotective role of GPR37L1 during ischemia suggests potential for agonist development, and antibodies would be essential for confirming the cellular and subcellular sites of drug action . Alternatively, function-blocking antibodies against specific domains of GPR37L1 might themselves serve as therapeutic agents if receptor inhibition proves beneficial in certain conditions. For cell-based therapies, GPR37L1 antibodies could help characterize and select optimally therapeutic astrocyte populations based on receptor expression levels . As precision medicine advances, immunohistochemistry with GPR37L1 antibodies on patient biopsies might identify individuals most likely to benefit from receptor-targeted therapies, particularly in conditions where glial-neuronal communication is disrupted, such as stroke, traumatic brain injury, or neurodegenerative diseases.